Specialty pharmacies reduce administrative burden and total cost of care as advanced therapies move to community sites, Fran ...
Pirtobrutinib plus venetoclax-rituximab reduced progression/death risk versus venetoclax-rituximab alone in R/R CLL/SLL, with higher undetectable MRD rates at 10–6. Head-to-head FLT3 inhibition in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results